 |
市場調査レポート
商品コード
1455147
アトピー性皮膚炎治療薬の世界市場規模、シェア、成長分析：投与経路別、薬剤クラス別 - 産業予測（2024年～2031年）Global Atopic Dermatitis Drugs Market Size, Share, Growth Analysis, By Route of administration(Topical, injection and others), By Drug class(Biologics, PDE4 inhibitors) - Industry Forecast 2024-2031 |
||||||
| アトピー性皮膚炎治療薬の世界市場規模、シェア、成長分析：投与経路別、薬剤クラス別 - 産業予測（2024年～2031年） |
|
出版日: 2024年03月18日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
アトピー性皮膚炎治療薬の世界市場規模は、2022年に136億5,000万米ドルと評価され、2023年の149億1,000万米ドルから2031年には301億4,000万米ドルに成長し、予測期間中（2024年～2031年）のCAGRは9.2％で成長する見通しです。
製薬業界では、湿疹とも呼ばれるアトピー性皮膚炎の治療薬の開発、製造、流通が、ダイナミックで急成長している世界の皮膚炎治療薬市場の焦点となっています。アトピー性皮膚炎の世界の有病率の上昇と、安全で効率的な治療法に対するニーズの高まりにより、この業界は大幅な拡大を経験しています。著名な製薬企業は激しい競争に巻き込まれ、アトピー性皮膚炎患者の満たされていない要求に対応するため、革新的な薬剤や治療法の提示に努めています。技術開発としては、標的ドラッグデリバリーシステム、症状モニタリングと管理のためのウェアラブル、アトピー性皮膚炎患者の遠隔診察と個別治療を可能にする遠隔医療プラットフォームなどがあり、これらも業界を支援しています。コルチコステロイド外用薬、カルシニューリン阻害薬、免疫調節薬、生物学的製剤は、市販されている数多くの治療法のほんの一部に過ぎず、それぞれに特別な作用機序と利点があります。技術開発としては、標的ドラッグデリバリーシステム、症状を追跡・管理するためのウェアラブル、アトピー性皮膚炎患者の遠隔診察や個別治療を可能にする遠隔医療プラットフォームなどがあり、これらも業界を助けています。精密医療と個別化医療は、患者の満足度と治療の成功率を向上させるために焦点を絞った医薬品を中心に人気を集めています。この業界における革新は、戦略的パートナーシップ、研究開発イニシアティブ、技術の向上によっても推進されています。これらの要因によって、アトピー性皮膚炎の人々によりカスタマイズされた効果的なソリューションが提供され、明るい未来が約束されています。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- 二次・一次情報源
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
アトピー性皮膚炎治療薬の世界市場：投与経路別
- 市場概要
- 局所
- 注射
- その他
アトピー性皮膚炎治療薬の世界市場：薬剤クラス別
- 市場概要
- 生物製剤
- PDE4阻害剤
- コルチコステロイド
- その他
アトピー性皮膚炎治療薬の世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ
- 中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Pfizer Inc.（US）
- Sanofi（France）
- AbbVie Inc.（US）
- GALDERMA LABORATORIES, L.P.（Switzerland）
- Eli Lilly and Company（US）
- Regeneron Pharmaceuticals Inc.（US）
- LEO Pharma Inc.（Denmark）
- Otsuka Pharmaceutical Co., Ltd.（Japan）
- Novartis AG（Switzerland）
- Incyte Corporation（US）
- Astellas Pharma Inc.（Japan）
- Bristol Myers Squibb（US）
- Johnson & Johnson（US）
- Takeda Pharmaceutical Company Limited（Japan）
- GlaxoSmithKline plc（UK）
- Boehringer Ingelheim International GmbH（Germany）
- Celgene Corporation（US）
- Meda AB（Sweden）
- Pierre Fabre Group（France）
- Bayer AG（Germany）
Global Atopic Dermatitis Drugs Market size was valued at USD 13.65 billion in 2022 and is poised to grow from USD 14.91 billion in 2023 to USD 30.14 billion by 2031, growing at a CAGR of 9.2% during the forecast period (2024-2031).
In the pharmaceutical industry, the development, manufacturing, and distribution of drugs for the treatment of atopic dermatitis, also referred to as eczema, is the focus of the dynamic and quickly growing global dermatitis drugs market. Due to the rising global prevalence of atopic dermatitis and the rising need for safe and efficient treatment alternatives, the industry has experienced substantial expansion. Prominent pharmaceutical corporations are involved in intense rivalry, endeavoring to present innovative medications and treatments to address the unfulfilled requirements of atopic dermatitis patients. Technological developments include targeted drug delivery systems, wearables for symptom monitoring and management, and telemedicine platforms that allow for remote consultations and individualized treatment for people with atopic dermatitis are also helping the industry. Topical corticosteroids, calcineurin inhibitors, immunomodulators, and biologic medicines are only a few of the many therapeutic methods available on the market; each has a special mode of action and advantages. Technological developments include targeted drug delivery systems, wearables for tracking and controlling symptoms, and telemedicine platforms that allow for remote consultations and individualized treatment for people with atopic dermatitis are also helping the industry. Precision medicine and personalized care are gaining popularity, with a focus on focused medicines to improve patient satisfaction and treatment success. Innovation in this industry is also being driven by strategic partnerships, R&D initiatives, and technology improvements. These factors promise a bright future with more customized and effective solutions for people with atopic dermatitis.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Atopic Dermatitis Drugs Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Atopic Dermatitis Drugs Market Segmental Analysis
The medicine class, region, and mode of administration are the three main segments of the global market for atopic dermatitis drugs. The market can be divided into injectable, topical, and other categories based on the mode of administration. The market is divided into segments based on drug class, including biologics, PDE4 inhibitors, corticosteroids, and others. The market is divided into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America based on geographic factors.
Drivers of the Global Atopic Dermatitis Drugs Market
The rising incidence of atopic dermatitis throughout the globe is one of the main factors propelling the global market for atopic dermatitis drugs. Atopic dermatitis is a widespread, long-lasting inflammatory skin disease that affects a large number of people worldwide, both adults and children. Numerous variables, including lifestyle modifications, environmental triggers, and genetic predisposition, might be blamed for the increasing prevalence of atopic dermatitis. The increasing number of people affected by atopic dermatitis is increasing the need for efficient treatment alternatives that will reduce symptoms and enhance their quality of life. Pharmaceutical businesses now have a favorable market environment in which to develop and launch new medications and therapies as a result of the increased demand.
Restraints in the Global Atopic Dermatitis Drugs Market
The high price of medications for atopic dermatitis is a significant barrier to the global market for these treatments. Numerous cutting-edge treatments, such biologics, can be costly, which limits some patient populations' access to them. The high cost of these drugs may discourage people from using them and have a minor negative effect on the expansion of the market as a whole.
Market Trends of the Global Atopic Dermatitis Drugs Market
The growing emphasis on biologic therapy is a significant market trend in the global market for drugs treating atopic dermatitis. Treatment for moderate-to-severe atopic dermatitis has seen a major increase in interest in and acceptance of biologic medicines, such as monoclonal antibodies. With a focused approach to illness management, these medicines specifically target molecules and pathways involved in the immune response linked to the ailment. Because of their great efficacy and capacity for long-lasting remission, biologic treatments are becoming more and more popular as a viable therapy choice for patients who have not reacted well to conventional medications. This pattern illustrates how the field of atopic dermatitis is moving toward precision medicine and individualized treatment plans.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Atopic Dermatitis Drugs Market by Route of administration
- Market Overview
- Topical
- injection and others
Global Atopic Dermatitis Drugs Market by Drug class
- Market Overview
- Biologics
- PDE4 inhibitors
- corticosteroids and others
Global Atopic Dermatitis Drugs Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GALDERMA LABORATORIES, L.P. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- LEO Pharma Inc. (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Otsuka Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Incyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Celgene Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Meda AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pierre Fabre Group (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
